Last reviewed · How we verify
Neostigmine w/ Glycopyrrolate
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects. Used for Myasthenia gravis, Reversal of neuromuscular blockade.
At a glance
| Generic name | Neostigmine w/ Glycopyrrolate |
|---|---|
| Sponsor | University of Texas Southwestern Medical Center |
| Drug class | Acetylcholinesterase inhibitor with anticholinergic agent |
| Target | Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at the neuromuscular junction and in the central and peripheral nervous systems. Glycopyrrolate is an anticholinergic agent added to this combination to prevent excessive muscarinic stimulation (salivation, bronchospasm, bradycardia) that would otherwise result from neostigmine monotherapy. Together, they enhance nicotinic effects while minimizing unwanted muscarinic effects.
Approved indications
- Myasthenia gravis
- Reversal of neuromuscular blockade
Common side effects
- Salivation
- Bronchospasm
- Bradycardia
- Muscle fasciculations
- Nausea
Key clinical trials
- Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: